Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

Consultation begins on new patient access scheme

EMA hopes PRIME will improve development of prioritymedicines and ease access concerns

- PMLiVE

Vertex forges ties with gene editing firm CRISPR Therapeutics

Aims to find new treatments for genetic diseases such as cystic fibrosis

- PMLiVE

Amgen’s Imlygic recommended for European approval

First-in-class oncolytic immunotherapy wins CHMP positive opinion

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

Clare

Lucid Group appoints new MD for Leading Edge

New MD at Leading Edge

Lucid Group Communications Limited

- PMLiVE

Choosing wisely

How to make the best of emerging markets

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

MRN expands operations with new senior director

Todd McGrath joins from Parexel

- PMLiVE

Valeant adds member to board of directors

President of ValueAct Capital G. Mason Morfitadded to team

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

- PMLiVE

AZ moves a step closer to gout drug approval in US

Final verdict to be delivered in end of December

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links